Hetero Labs Ltd Vi Company Profile
What is the competitive landscape for HETERO LABS LTD VI
HETERO LABS LTD VI has seven approved drugs.
Drugs and US Patents for Hetero Labs Ltd Vi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero Labs Ltd Vi | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 215460-002 | Jun 14, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 217925-001 | Jan 27, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | PLERIXAFOR | plerixafor | SOLUTION;SUBCUTANEOUS | 217560-001 | Jun 16, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 212204-001 | May 3, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 215765-001 | Oct 15, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Vi | DECITABINE | decitabine | INJECTABLE;INTRAVENOUS | 215355-001 | May 10, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

